Aclaris Therapeutics (ACRS) Change in Receivables (2018 - 2025)
Aclaris Therapeutics (ACRS) recorded quarterly Change in Receivables of -$56000.0 in Q2 2025, up 17.65% quarter-over-quarter from -$68000.0 in Q1 2025, and down 16.67% on a YoY basis from -$67200.0 in Q2 2024.
Aclaris Therapeutics (ACRS) Change in Receivables (2018 - 2025) Analysis & Trends
Aclaris Therapeutics' Change in Receivables history runs 8 years deep, the most recent figure standing at -$56000.0 for Q2 2025.
- In Q2 2025, Change in Receivables fell 16.67% year-over-year to -$56000.0; the TTM figure through Jun 2025 stood at -$131000.0 (down 23.58% YoY), while the FY2024 annual figure was $20000.0, up 110.75% from the prior year.
- Change in Receivables was -$56000.0 for Q2 2025 at Aclaris Therapeutics, up from -$68000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $202000.0 in Q1 2023 to a low of -$255000.0 in Q2 2023.
- Historically, Change in Receivables has averaged -$32111.1 across 5 years, with a median of -$44000.0 in 2022.
- Biggest YoY gain for Change in Receivables was 1920.0% in 2023; the steepest drop was 6475.0% in 2023.
- A 5-year view of Change in Receivables shows it stood at -$188000.0 in 2021, then soared by 39.89% to -$113000.0 in 2022, then jumped by 57.52% to -$48000.0 in 2023, then jumped by 47.92% to -$25000.0 in 2024, then slumped by 124.0% to -$56000.0 in 2025.
- The last three Change in Receivables figures came in at -$56000.0 (Q2 2025), -$68000.0 (Q1 2025), and -$25000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Aclaris Therapeutics | 580.93 Mn | 580.93 Mn | 1.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -56,000.00 |
| Jun 30, 2025 | -56,000.00 |
| Mar 31, 2025 | -68,000.00 |
| Mar 31, 2025 | -68,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Sep 30, 2024 | 18,000.00 |
| Sep 30, 2024 | 18,000.00 |
| Jun 30, 2024 | -48,000.00 |
| Jun 30, 2024 | -48,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Dec 31, 2023 | -48,000.00 |
| Dec 31, 2023 | -48,000.00 |
| Sep 30, 2023 | -85,000.00 |
| Sep 30, 2023 | -85,000.00 |
| Jun 30, 2023 | -255,000.00 |
| Jun 30, 2023 | -255,000.00 |
| Mar 31, 2023 | 202,000.00 |
| Mar 31, 2023 | 202,000.00 |